TARG9
Glioblastoma, Triple-Negative Breast Cancer
Pre-clinicalActive
Key Facts
About Targinta
Targinta is a preclinical-stage biotech focused on novel targeted therapies for aggressive, hard-to-treat cancers. Its core asset is the proprietary target integrin α10β1, against which it is developing two lead candidates: TARG9, an ADC, and TARG10, a functional blocking antibody. The company is a wholly-owned subsidiary of the publicly traded parent company Xintela AB, leveraging this structure for funding and research support as it advances its programs toward clinical trials.
View full company profile